Patient-derived 3D mini tumors make it easier to choose treatment for cancer
CompanyASC Oncology GmbH, Berlin, Germany
To improve and facilitate the selection of a suitable drug therapy for cancer, ASC Oncology has developed the Reverse Clinical Engineering® test procedure. The personalized test procedure is suitable for patients with malignant, solid tumors, such as carcinomas or sarcomas. In the ASC Oncology laboratory, numerous three-dimensional “mini tumors” (PD3D® tumor organoids) are cultured from patients’ tumor tissue samples (obtained through biopsy or surgical resection), on which drugs can be safely tested. An automated screening platform with an integrated genetic data set analyses the exposed active ingredients and assesses cell viability. In addition, a sensitivity profile of the individual tumor model is created for each active ingredient tested. To make the predictions more precise, the test procedure can be expanded with additional options (e.g. sequencing, proteome analysis). Within an average of 28 days, the process generates meaningful results that are transmitted to doctors in accordance with data protection regulations. So far, it has been shown that Reverse Clinical Engineering® could correctly predict the effectiveness of drugs for tumor patients in up to 88% of cases and ineffectiveness in up to 100% of cases. In summary, it can be seen that the method enables an accelerated and personalized prediction of the effectiveness of various active ingredients, which can help doctors and their patients decide at an early stage on the safest and most effective drug treatment for cancer.
Krebs. Vor Behandlungsbeginn die Optionen testen. Im Labor. Ohne Nebenwirkungen.
www.asc-oncology.com
Added on: 01-18-2024
[1] https://www.asc-oncology.com/[2] https://www.asc-oncology.com/en/for-physicians/[3] https://www.bionity.com/en/news/1182473/curing-cancer-in-the-petri-dish.html?utm_source=newsletter&utm_medium=email&utm_campaign=bionityde&WT.mc_id=ca0264
